Diridavumab

Drug Profile

Diridavumab

Alternative Names: CR-6261; JNJ-54235025; mAb CR6261; Monoclonal antibody CR6261

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Crucell
  • Developer National Institute of Allergy and Infectious Diseases
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 03 Feb 2017 Janssen Pharmaceuticals withdraws prior to enrolment a phase I trial for Healthy volunteers in Japan (NCT02016066)
  • 24 Jan 2017 Diridavumab is still in phase II trials for Influenza-A virus infections in USA
  • 01 Jan 2015 Phase-II clinical trials in Influenza-A virus infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top